Bioxcel therapeutics aligns with fda recommendation for phase 3 trial for tranquility program, provides update on strategic financing, and reports third quarter 2023 financial results

Company plans to conduct phase 3 trial of bxcl501 in the at-home setting for tranquility program to support potential snda for acute treatment of agitation associated with dementia due to probable alzheimer's disease
BTAI Ratings Summary
BTAI Quant Ranking